Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of vormatrigine in adults with epilepsy
2025-521640-38-00Phase 3Authorised
- Sponsor
- Praxis Precision Medicines
- Start
- Oct 2025
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 10
01
Overview
Phase 3, open-label, single-arm trial of vormatrigine in epilepsy, Focal onset seizure and generalized tonic-clonic seizure (GTCS), sponsored by Praxis Precision Medicines. Primary endpoints: Incidence and severity of treatment-emergent adverse events, Change in vital signs and 3 more. Planned start Oct 2025; status: authorised.
02
Drugs
vormatrigine
03
Conditions
epilepsyFocal onset seizuregeneralized tonic-clonic seizure (GTCS)
Beyond the preview
Go deeper on 2025-521640-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521640-38-00.